Biogen Inc. (NASDAQ:BIIB) Stock Position Raised by Mather Group LLC.

Mather Group LLC. lifted its position in Biogen Inc. (NASDAQ:BIIB) by 476.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,728 shares of the biotechnology company’s stock after buying an additional 1,428 shares during the quarter. Mather Group LLC.’s holdings in Biogen were worth $264,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Grandfield & Dodd LLC grew its position in Biogen by 5.2% during the 3rd quarter. Grandfield & Dodd LLC now owns 1,261 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 62 shares during the last quarter. Quintet Private Bank Europe S.A. grew its holdings in shares of Biogen by 9.7% during the third quarter. Quintet Private Bank Europe S.A. now owns 710 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 63 shares during the last quarter. TD Private Client Wealth LLC increased its stake in shares of Biogen by 25.0% in the third quarter. TD Private Client Wealth LLC now owns 385 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 77 shares in the last quarter. Huntington National Bank raised its holdings in shares of Biogen by 3.5% in the third quarter. Huntington National Bank now owns 2,308 shares of the biotechnology company’s stock valued at $447,000 after buying an additional 79 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in Biogen by 1.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,018 shares of the biotechnology company’s stock worth $767,000 after buying an additional 79 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Ratings Changes

BIIB has been the subject of a number of research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Biogen from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Monday, November 4th. Wells Fargo & Company dropped their price objective on shares of Biogen from $190.00 to $165.00 and set an “equal weight” rating for the company in a research report on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $300.00 target price on shares of Biogen in a research note on Thursday, October 31st. William Blair restated an “outperform” rating on shares of Biogen in a research report on Monday, January 13th. Finally, Bank of America reiterated a “neutral” rating and issued a $178.00 price target on shares of Biogen in a report on Tuesday, December 10th. Sixteen analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $228.80.

Biogen Stock Performance

Shares of BIIB opened at $142.37 on Friday. The stock has a market capitalization of $20.75 billion, a price-to-earnings ratio of 12.86, a PEG ratio of 1.66 and a beta of -0.08. Biogen Inc. has a 12 month low of $139.71 and a 12 month high of $246.44. The firm has a fifty day simple moving average of $149.88 and a 200 day simple moving average of $176.96. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.